Moderate Evidence
Research Overview
Follistatin Research for Sporadic Inclusion Body Myositis
An evidence-based overview of research examining Follistatin in the context of sporadic inclusion body myositis. This page synthesizes findings from peer-reviewed literature.
Research Summary
Follistatin gene therapy improved 6MWT by +56 m/year vs -25.8 m/year natural decline in sIBM patients. This rare muscle disease has no approved treatments, making follistatin gene therapy a promising approach.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Follistatin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.